Last reviewed · How we verify
Oral Anticoagulant (oral-anticoagulant)
Inhibits Factor Xa to block the intrinsic and extrinsic coagulation pathways, preventing thrombin generation and clot formation.
Pfizer's oral anticoagulant currently holds no approved indications and is not among the leading drugs in the market, facing strong competition from established players like Apixaban and Rivaroxaban. The drug's mechanism of inhibiting Factor Xa to prevent clot formation aligns with other leading oral anticoagulants but lacks the broad indication approvals and robust clinical data of its competitors. A key risk is the lack of approved indications and the requirement for a PD-L1 companion diagnostic, which may limit its market penetration and adoption. Despite these challenges, the extensive clinical trial program involving 25 studies suggests a promising pipeline that could lead to future approvals and market expansion.
At a glance
| Generic name | oral-anticoagulant |
|---|---|
| Sponsor | Pfizer Inc. |
| Drug class | Direct oral anticoagulant (DOAC); Factor Xa inhibitor |
| Target | Factor Xa (coagulation Factor X, activated form) |
| Therapeutic area | Cardiovascular |
| Phase | discontinued |
Mechanism of action
Oral anticoagulants in the Factor Xa inhibitor class work by selectively blocking Factor Xa, a serine protease critical to both the intrinsic and extrinsic pathways of the coagulation cascade. Factor Xa catalyzes the conversion of prothrombin to thrombin, the enzyme responsible for converting fibrinogen to fibrin and forming stable blood clots. By inhibiting Factor Xa, these drugs reduce thrombin generation and prevent the formation of pathologic thrombi that cause stroke, deep vein thrombosis, and pulmonary embolism. Unlike warfarin, which requires hepatic synthesis of vitamin K-dependent factors and has a narrow therapeutic window, Factor Xa inhibitors offer predictable pharmacokinetics, rapid onset, and no requirement for routine coagulation monitoring. The selectivity for Factor Xa over other serine proteases in the coagulation cascade provides a favorable safety profile with lower rates of major bleeding compared to older anticoagulants in many patient populations.
Approved indications
Pipeline indications
- Cryptogenic ischemic stroke with patent foramen ovale (PFO) — Phase 3
- Polycythemia vera and essential thrombocythemia (thromboembolism prevention) — Phase 3
- Left ventricular thrombus — Phase 2
- Mechanical heart valve thrombosis prevention — Phase 3
- Secondary stroke prevention in older adults — Phase 3
Common side effects
Drug interactions
- Strong CYP3A4 inhibitors (ritonavir, ketoconazole, itraconazole)
- Strong CYP3A4 inducers (rifampin, phenytoin, carbamazepine)
- Antiplatelet agents (aspirin, clopidogrel, NSAIDs)
- Other anticoagulants (warfarin, heparin, other DOACs)
- P-glycoprotein inhibitors (verapamil, diltiazem, amiodarone)
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Oral Anticoagulant CI brief — competitive landscape report
- Oral Anticoagulant updates RSS · CI watch RSS
- Pfizer Inc. portfolio CI